link
Bookmarks
Hodgkin Lymphoma
Virginia Barnes Planz, MD; Hollins Clark, MD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe
1
0
0
0

KEY FACTS

  • Imaging

    • Top Differential Diagnoses

      • Diagnostic Checklist

        TERMINOLOGY

        • Definitions

          • Hodgkin lymphoma (HL): Malignancy of lymphocytes with Reed-Sternberg cells
            • Pathologic subtypes: Nodular sclerosis (most common), mixed cellularity, lymphocyte depleted, lymphocyte rich
            • Clinically, enlarged lymph nodes (LNs) with spread in contiguous fashion to other LNs, viscera, or bone marrow
            • Bulky disease refers to multiple coalescing involved LNs

        IMAGING

        • F-18 FDG PET/CT Findings

          • F-18 FDG PET/MR Findings

            • CT and MR Findings

              DIFFERENTIAL DIAGNOSIS

                CLINICAL ISSUES

                • Presentation

                  • Demographics

                    • Natural History & Prognosis

                      • Treatment

                        DIAGNOSTIC CHECKLIST

                        • Image Interpretation Pearls

                          Selected References

                          1. Giraudo C et al: 18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol. 51(3):163-9, 2016
                          2. Platzek I: (18)F-Fluorodeoxyglucose PET/MR imaging in lymphoma. PET Clin. 11(4):363-73, 2016
                          3. National Cancer Institute. SEER Stat Fact Sheets: Hodgkin Lymphoma. http://seer.cancer.gov/statfacts/html/hodg.html. Accessed July 31, 2015
                          4. Barrington SF et al: Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 32(27):3048-58, 2014
                          5. Cheson BD et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 32(27):3059-68, 2014
                          6. Platzek I et al: PET/MR for therapy response evaluation in malignant lymphoma: initial experience. MAGMA. 26(1):49-55, 2013
                          7. Saboo SS et al: Spleen in haematological malignancies: spectrum of imaging findings. Br J Radiol. 85(1009):81-92, 2012
                          8. Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol. 29(14):1844-54, 2011
                          9. Paes FM et al: FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 30(1):269-91, 2010
                          10. Bower M et al: British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 9(6):336-88, 2008
                          11. Schöder H et al: PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am. 46(2):225-41, 2008
                          12. Raanani P et al: Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol. 17(1):117-22, 2006
                          Related Anatomy
                          Loading...
                          Related Differential Diagnoses
                          Loading...
                          References
                          Tables

                          Tables

                          KEY FACTS

                          • Imaging

                            • Top Differential Diagnoses

                              • Diagnostic Checklist

                                TERMINOLOGY

                                • Definitions

                                  • Hodgkin lymphoma (HL): Malignancy of lymphocytes with Reed-Sternberg cells
                                    • Pathologic subtypes: Nodular sclerosis (most common), mixed cellularity, lymphocyte depleted, lymphocyte rich
                                    • Clinically, enlarged lymph nodes (LNs) with spread in contiguous fashion to other LNs, viscera, or bone marrow
                                    • Bulky disease refers to multiple coalescing involved LNs

                                IMAGING

                                • F-18 FDG PET/CT Findings

                                  • F-18 FDG PET/MR Findings

                                    • CT and MR Findings

                                      DIFFERENTIAL DIAGNOSIS

                                        CLINICAL ISSUES

                                        • Presentation

                                          • Demographics

                                            • Natural History & Prognosis

                                              • Treatment

                                                DIAGNOSTIC CHECKLIST

                                                • Image Interpretation Pearls

                                                  Selected References

                                                  1. Giraudo C et al: 18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol. 51(3):163-9, 2016
                                                  2. Platzek I: (18)F-Fluorodeoxyglucose PET/MR imaging in lymphoma. PET Clin. 11(4):363-73, 2016
                                                  3. National Cancer Institute. SEER Stat Fact Sheets: Hodgkin Lymphoma. http://seer.cancer.gov/statfacts/html/hodg.html. Accessed July 31, 2015
                                                  4. Barrington SF et al: Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 32(27):3048-58, 2014
                                                  5. Cheson BD et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 32(27):3059-68, 2014
                                                  6. Platzek I et al: PET/MR for therapy response evaluation in malignant lymphoma: initial experience. MAGMA. 26(1):49-55, 2013
                                                  7. Saboo SS et al: Spleen in haematological malignancies: spectrum of imaging findings. Br J Radiol. 85(1009):81-92, 2012
                                                  8. Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol. 29(14):1844-54, 2011
                                                  9. Paes FM et al: FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 30(1):269-91, 2010
                                                  10. Bower M et al: British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 9(6):336-88, 2008
                                                  11. Schöder H et al: PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am. 46(2):225-41, 2008
                                                  12. Raanani P et al: Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol. 17(1):117-22, 2006